menu
    • menu

    Find Dabrafenib Mesylate manufacturers, exporters & distributors on PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    14

    API Suppliers

    API Suppliers

    1

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    13

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 78,477

    MARKET PLACE

    3

    API

    1

    FDF

    15INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    18

    FDF Dossiers

    FDF Dossiers

    5

    FDA Orange Book

    FDA (Orange Book)

    5

    Europe

    Europe

    0

    Canada

    Canada

    6

    Australia

    Australia

    2

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    11DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    68

    US Patents

    28

    US Exclusivities

    2

    Health Canada Patents

    DIGITAL CONTENT

    3

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    44

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    11,709

    Finished Drug Prices

    Listed Dossiers

    108 RELATED EXCIPIENT COMPANIES

    182EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 1195768-06-9, Dabrafenib (mesylate), Gsk 2118436b, Dabrafenib mesilate, Dabrafenib mesylate [usan], Unii-b6dc89i63e
    Molecular Formula
    C24H24F3N5O5S3
    Molecular Weight
    615.7  g/mol
    InChI Key
    YKGMKSIHIVVYKY-UHFFFAOYSA-N
    FDA UNII
    B6DC89I63E
    Dabrafenib Mesylate
    Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
    1 2D Structure

    Dabrafenib Mesylate

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic acid
    2.1.2 InChI
    InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)
    2.1.3 InChI Key
    YKGMKSIHIVVYKY-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    B6DC89I63E
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 1195768-06-9

    2. Dabrafenib (mesylate)

    3. Gsk 2118436b

    4. Dabrafenib Mesilate

    5. Dabrafenib Mesylate [usan]

    6. Unii-b6dc89i63e

    7. Gsk-2118436 Mesylate

    8. Gsk-2118436b

    9. Methane Sulfonate Salt

    10. Gsk2118436b

    11. Gsk2118436 Mesylate

    12. B6dc89i63e

    13. Chebi:75048

    14. Gsk-2118436b Mesylate

    15. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide Methanesulfonate

    16. Gsk2118436b, Methane Sulfonate Salt

    17. Gsk-2118436 Methanesulfonate Salt

    18. Gsk-2118436b Methanesulfonate Salt

    19. Gsk2118436 Mesylate;gsk 2118436b

    20. Dabrafenib Mesilate (jan)

    21. Dabrafenib Mesylate (gsk-2118436)

    22. Dabrafenib Mesylate (usan)

    23. Dabrafenib Mesilate [jan]

    24. Taflinar

    25. N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic Acid

    26. Dabrafenib Methanesulfonate

    27. Tafinlar (tn)

    28. Gsk2118436 Methane Sulfonate Salt

    29. Dabrafenib Monomesylate

    30. Gsk 2118436 Mesylate

    31. Schembl1127269

    32. Chembl2105729

    33. Dabrafenib Mesylate [mi]

    34. Dtxsid70152500

    35. Amy30045

    36. Bcp04738

    37. Ex-a1559

    38. Dabrafenib Mesilate [who-dd]

    39. Hy-14660a

    40. Mfcd20922872

    41. S5069

    42. Akos025396661

    43. Ccg-270246

    44. Cs-1641

    45. Dabrafenib Mesylate [orange Book]

    46. Ac-31302

    47. As-17010

    48. Ft-0696677

    49. D10104

    50. A903491

    51. Sr-01000941590

    52. Sr-01000941590-1

    53. Q27145089

    54. Gsk2118436 Ms Salt, Dabrafenib Ms Salt, Gsk2118436a Ms Salt

    55. Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)- 2-fluorophenyl)-2,6-difluoro-, Methanesulfonate (1:1)

    56. Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, Methanesulfonate (1:1)

    57. Dabrafenib Mesylaten-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide, Methanesulfonic Acid; Dabrafenib Mesylate

    58. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl)-2,6- Difluorobenzenesulfonamide Monomethanesulfonate

    59. N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate

    60. N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate

    2.3.2 Other Synonyms

    1. 1195765-45-7

    2. Dabrafenib

    2.4 Create Date
    2009-12-22
    3 Chemical and Physical Properties
    Molecular Weight 615.7 g/mol
    Molecular Formula C24H24F3N5O5S3
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count14
    Rotatable Bond Count6
    Exact Mass615.08916689 g/mol
    Monoisotopic Mass615.08916689 g/mol
    Topological Polar Surface Area210 Ų
    Heavy Atom Count40
    Formal Charge0
    Complexity910
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    * Melanoma:

    Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4. 4 and 5. 1).

    * Adjuvant treatment of melanoma:

    Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

    * Non-small cell lung cancer (NSCLC):

    Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.

    Treatment of melanoma, Treatment of solid malignant tumours (excluding melanoma)

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    L01EC02

    API SUPPLIERS

    read-more
    read-more

    01

    Fermion Oy

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothWith Fermion, start the journey of your innovative API.

    Contact Supplier Contact Supplier
    Flag Finland
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    fermion

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Jinan Tantu Chemicals

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Jinan Tantu Chemicals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Sichuan Elixir Pharmaceuticals

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Sichuan Elixir Pharmaceuticals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    MSN Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 31080

    Submission : 2016-11-10

    Status : Active

    Type : II

     CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-09-02

    Valid Till : 2025-05-05

    Written Confirmation Number : WC-0349

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 54893-0052

    Start Marketing Date : 2016-10-26

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Guangdong Raffles PharmaTech Co Lt...

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    06

    Guangdong Raffles PharmaTech Co Lt...

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    07

    Shenzhen HwaGen Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Shenzhen HwaGen Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Beijing Mesochem Technology

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    09

    Hangzhou Longshine Bio-Tech

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Hangzhou Longshine Bio-Tech

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Shenzhen Haorui

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690741800,"product":"DABRAFENIB MESYLATE","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"'TO THE ORDER","customerCountry":"CANADA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"80000","totalValueFC":"23543.1","currency":"USD","unitRateINR":6449999.0099999998,"date":"31-Jul-2023","totalValueINR":"1934999.703","totalValueInUsd":"23543.1","indian_port":"HYDERABAD AIR","hs_no":"29335920","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""}]
    31-Jul-2023
    31-Jul-2023
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    INTERMEDIATES SUPPLIERS

    read-more
    read-more

    01

    Jinan Tantu Chemicals

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

    2,6-Difluorobenzenesulfonyl chloride

    CAS Number : 60230-36-6

    End Use API : Dabrafenib Mesylate

    About The Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our cor...

    Jinan Tantu Chemicals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Jinan Tantu Chemicals

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

    Methyl 3-amino-2-fluorobenzoate

    CAS Number : 1195768-18-3

    End Use API : Dabrafenib Mesylate

    About The Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our cor...

    Jinan Tantu Chemicals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Jinan Tantu Chemicals

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

    2-chloro-4-methylpyrimidine

    CAS Number : 13036-57-2

    End Use API : Dabrafenib Mesylate

    About The Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our cor...

    Jinan Tantu Chemicals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Jinan Tantu Chemicals

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

    2,2-Dimethylthiopropionamide

    CAS Number : 630-22-8

    End Use API : Dabrafenib Mesylate

    About The Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our cor...

    Jinan Tantu Chemicals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Guangdong Raffles PharmaTech Co Ltd

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1,1-diethyleth...

    CAS Number : 1195768-23-0

    End Use API : Dabrafenib Mesylate

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Guangdong Raffles PharmaTech Co Ltd

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    N-{3-[(2-chloro-4-pyrimidinyl)acetyl]-2-fluorophen...

    CAS Number : 1195768-20-7

    End Use API : Dabrafenib Mesylate

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Guangdong Raffles PharmaTech Co Ltd

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Methyl 3-((2,6-difluorophenyl)sulfonamido)-2-fluor...

    CAS Number : 1195768-19-4

    End Use API : Dabrafenib Mesylate

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Guangdong Raffles PharmaTech Co Ltd

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Methyl 3-amino-2-fluorobenzoate

    CAS Number : 1195768-18-3

    End Use API : Dabrafenib Mesylate

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Guangdong Raffles PharmaTech Co Ltd

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    2,2,2-trimethylthioacetamide

    CAS Number : 630-22-8

    End Use API : Dabrafenib Mesylate

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Hangzhou Longshine Bio-Tech Co.,LTD

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Hangzhou Longshine Bio-Tech Co.,LTD

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    2-chloro-4-methylpyrimidine

    CAS Number : 13036-57-2

    End Use API : Dabrafenib Mesylate

    About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - CAPSULE;ORAL - EQ 50MG BASE

    USFDA APPLICATION NUMBER - 202806

    read-more

    DOSAGE - CAPSULE;ORAL - EQ 75MG BASE

    USFDA APPLICATION NUMBER - 202806

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    US Patents

    read-more
    read-more

    01

    NOVARTIS

    DABRAFENIB MESYLATE

    arrow
    DDL Conference
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    DDL Conference
    Not Confirmed

    Patent Expiration Date : 2030-10-15

    DABRAFENIB MESYLATE

    US Patent Number : 8703781

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 202806

    Patent Use Code : U-2298

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2030-10-15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    NOVARTIS

    DABRAFENIB MESYLATE

    arrow
    DDL Conference
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    DDL Conference
    Not Confirmed

    Patent Expiration Date : 2029-05-04

    DABRAFENIB MESYLATE

    US Patent Number : 9233956

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 202806

    Patent Use Code : U-2031

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2029-05-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    NOVARTIS

    DABRAFENIB MESYLATE

    arrow
    DDL Conference
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    DDL Conference
    Not Confirmed

    Patent Expiration Date : 2038-12-29

    DABRAFENIB MESYLATE

    US Patent Number : 11504333*PED

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 217514

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-12-29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    NOVARTIS

    DABRAFENIB MESYLATE

    arrow
    DDL Conference
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    DDL Conference
    Not Confirmed

    Patent Expiration Date : 2030-01-20

    DABRAFENIB MESYLATE

    US Patent Number : 7994185

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 202806

    Patent Use Code : U-2296

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2030-01-20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    NOVARTIS

    DABRAFENIB MESYLATE

    arrow
    DDL Conference
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    DDL Conference
    Not Confirmed

    Patent Expiration Date : 2031-04-15

    DABRAFENIB MESYLATE

    US Patent Number : 8952018*PED

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 202806

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2031-04-15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    NOVARTIS

    DABRAFENIB MESYLATE

    arrow
    DDL Conference
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    DDL Conference
    Not Confirmed

    Patent Expiration Date : 2030-01-20

    DABRAFENIB MESYLATE

    US Patent Number : 8415345

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 202806

    Patent Use Code : U-2296

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2030-01-20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    NOVARTIS

    DABRAFENIB MESYLATE

    arrow
    DDL Conference
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    DDL Conference
    Not Confirmed

    Patent Expiration Date : 2030-01-20

    DABRAFENIB MESYLATE

    US Patent Number : 7994185

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 217514

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2030-01-20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    NOVARTIS

    DABRAFENIB MESYLATE

    arrow
    DDL Conference
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    DDL Conference
    Not Confirmed

    Patent Expiration Date : 2030-10-15

    DABRAFENIB MESYLATE

    US Patent Number : 8703781

    Drug Substance Claim : Y

    Drug Product Claim : Y

    Application Number : 202806

    Patent Use Code : U-2296

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2030-10-15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    NOVARTIS

    DABRAFENIB MESYLATE

    arrow
    DDL Conference
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    DDL Conference
    Not Confirmed

    Patent Expiration Date : 2025-06-10

    DABRAFENIB MESYLATE

    US Patent Number : 8835443

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 217514

    Patent Use Code : U-3565

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2025-06-10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    NOVARTIS

    DABRAFENIB MESYLATE

    arrow
    DDL Conference
    Not Confirmed

    NOVARTIS

    Switzerland
    arrow
    DDL Conference
    Not Confirmed

    Patent Expiration Date : 2025-06-10

    DABRAFENIB MESYLATE

    US Patent Number : 8835443

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 202806

    Patent Use Code : U-2027

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2025-06-10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search